Clostridium difficile Biologic Research and Development; May 2014




Clostridium difficile Biologic Research & Development

Antibiotic administration is a risk factor for Clostridium difficile-associated disease (CDAD).

Excretion of antibiotics into the intestinal tract may lead to an alteration of the normal microflora, resulting in overgrowth of pathogenic bacteria including Clostridium difficile.       Stiefel, et al. have previously reported that oral administration of β-lactamase enzyme inactivates ampicillin and piperacillin in the small intestine. This study evaluates oral β-lactamase administration in combination with parenteral piperacillin or ampicillin in mice to validate the hypothesis that oral β-lactamase protects the microbiota and prevents          Clostridium difficile infection (CDI).


Brian Andresen, Chairperson of Biologic Research and Development Committee   (*)              *Michael Kaleko, MD, PhD, Senior Vice President, Reseaerch & Development Synthetic Biologics  *Joseph Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs, Synthetic Biolgics *Andy Bristol, PhD, Vice President, Research & Development, Synthetic Biologics                   *Lewis Barrett, Senior Vice President, Commercial Strategy, Synthetic Biologics